Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives.

The new millennium has brought intense focus of interest on the risk of cardiovascular disease in women. The polycystic ovary syndrome (PCOS) is a common endocrine disorder in women characterised by hyperandrogenism and oligomenorrhoea. Most women with PCOS also exhibit features of the metabolic syndrome, including insulin resistance, obesity and dyslipidaemia. While the association with type 2 diabetes is well established, whether the incidence of cardiovascular disease is increased in women with PCOS remains unclear. Echocardiography, imaging of coronary and carotid arteries, and assessments of both endothelial function and arterial stiffness have recently been employed to address this question. These studies have collectively demonstrated both structural and functional abnormalities of the cardiovascular system in PCOS. These alterations, however, appear to be related to the presence of individual cardiovascular risk factors, particularly insulin resistance, rather than to the presence of PCOS and hyperandrogenaemia per se. However, given the inferential nature of the evidence to date, more rigorous cohort studies of long-term cardiovascular outcomes and clinical trials of risk factor modification are required in women with PCOS.

[1]  D. Brutsaert,et al.  Diastolic failure: pathophysiology and therapeutic implications. , 1993, Journal of the American College of Cardiology.

[2]  M. Davies,et al.  Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. , 2001, Human reproduction.

[3]  J. Shaw,et al.  Waist circumference, waist–hip ratio and body mass index and their correlation with cardiovascular disease risk factors in Australian adults , 2003, Journal of internal medicine.

[4]  M. Matsuda,et al.  Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. , 2002, Diabetes.

[5]  Diederick E Grobbee,et al.  Carotid intima–media thickness, arterial stiffness and risk of cardiovascular disease: current evidence , 2002, Journal of hypertension.

[6]  S. Daya,et al.  Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome. , 1999, Human reproduction.

[7]  A. Pfeiffer,et al.  Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome , 2004 .

[8]  A. Tavridou,et al.  Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. , 2005, The Journal of clinical endocrinology and metabolism.

[9]  Constance K Haan,et al.  Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women , 2004, Circulation.

[10]  J. Connell,et al.  Low grade chronic inflammation in women with polycystic ovarian syndrome. , 2001, The Journal of clinical endocrinology and metabolism.

[11]  G. Davı̀,et al.  Platelet activation in obese women: role of inflammation and oxidant stress. , 2002, JAMA.

[12]  W. Dodson,et al.  Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. , 1999, The Journal of clinical endocrinology and metabolism.

[13]  G. London,et al.  Arterial stiffness and function in end-stage renal disease. , 2004, Advances in chronic kidney disease.

[14]  Richard Kahn,et al.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. , 2005, Diabetes care.

[15]  J. Cameron,et al.  Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. , 2005, The Journal of clinical endocrinology and metabolism.

[16]  B. Strauer,et al.  Left Ventricular Diastolic Dysfunction as an Early Manifestation of Diabetic Cardiomyopathy , 2002, Cardiology.

[17]  P. Hardiman,et al.  Internal carotid artery haemodynamics in women with polycystic ovaries. , 2000, Clinical science.

[18]  T. Key,et al.  Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. , 1998, The Journal of clinical endocrinology and metabolism.

[19]  G. Conway,et al.  Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome , 1992, Clinical endocrinology.

[20]  A. Baron Insulin resistance and vascular function. , 2002, Journal of diabetes and its complications.

[21]  N. Goldenberg,et al.  Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. , 2003, Metabolism: clinical and experimental.

[22]  E. Bixler,et al.  Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. , 2001, The Journal of clinical endocrinology and metabolism.

[23]  C. Berne,et al.  Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? , 1996, Human reproduction.

[24]  G. Chrousos,et al.  Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. , 2005, The Journal of clinical endocrinology and metabolism.

[25]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[26]  G. Watts,et al.  Coenzyme Q10 and diabetic endotheliopathy: oxidative stress and the 'recoupling hypothesis'. , 2004, QJM : monthly journal of the Association of Physicians.

[27]  D. Meeking,et al.  Cardiovascular risk in women with polycystic ovarian syndrome (PCOS) , 2005, Journal of Clinical Pathology.

[28]  M. Sampson,et al.  Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI‐1) activity in lean women with and without the polycystic ovary syndrome , 1996, Clinical endocrinology.

[29]  E. Barrett-Connor,et al.  Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women , 1995, BMJ.

[30]  C. Giannarelli,et al.  Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome. , 2005, Thrombosis research.

[31]  A. von Eckardstein,et al.  Androgens and coronary artery disease. , 2003, Endocrine reviews.

[32]  P. V. van Kesteren,et al.  Mortality and morbidity in transsexual subjects treated with cross‐sex hormones , 1997, Clinical endocrinology.

[33]  V. de Leo,et al.  Clinical, endocrine and metabolic effects of acarbose, an alpha-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance. , 2001, Human reproduction.

[34]  F. Orio,et al.  Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. , 2004, The Journal of clinical endocrinology and metabolism.

[35]  B. Corenblum,et al.  Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. , 2000, The Journal of clinical endocrinology and metabolism.

[36]  A. Oberg,et al.  Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. , 2003, The Journal of clinical endocrinology and metabolism.

[37]  L. Kuller,et al.  Evidence for Association Between Polycystic Ovary Syndrome and Premature Carotid Atherosclerosis in Middle-Aged Women , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[38]  J. Lekakis,et al.  Metformin administration improves endothelial function in women with polycystic ovary syndrome. , 2005, European journal of endocrinology.

[39]  D. Panidis,et al.  Serum adiponectin levels in women with polycystic ovary syndrome. , 2003, Human reproduction.

[40]  H. Yki-Järvinen Insulin resistance and endothelial dysfunction. , 2003, Best practice & research. Clinical endocrinology & metabolism.

[41]  H. White,et al.  Association between Polycystic Ovaries and Extent of Coronary Artery Disease in Women Having Cardiac Catheterization , 1997, Annals of Internal Medicine.

[42]  F. Orio,et al.  The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. , 2004, The Journal of clinical endocrinology and metabolism.

[43]  A Tremblay,et al.  Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. , 1990, Arteriosclerosis.

[44]  O. Zinder,et al.  Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. , 2004, The Journal of clinical endocrinology and metabolism.

[45]  Z. Katusic Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? , 2001, American journal of physiology. Heart and circulatory physiology.

[46]  A. Lanzone,et al.  Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. , 2003, Human reproduction.

[47]  M. Boscaro,et al.  Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome , 2004, Journal of endocrinological investigation.

[48]  D. Playford,et al.  SPECIAL ARTICLE: NON‐INVASIVE MEASUREMENT OF ENDOTHELIAL FUNCTION , 1998, Clinical and experimental pharmacology & physiology.

[49]  G. de Simone,et al.  Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. , 2002, Journal of the American College of Cardiology.

[50]  K. Segal,et al.  Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome , 1989, Diabetes.

[51]  A. Balen,et al.  Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? , 2002, Clinical endocrinology.

[52]  L. Kuller,et al.  Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. , 1998, Journal of clinical epidemiology.

[53]  P. McKeigue,et al.  Cardiovascular disease in women with polycystic ovary syndrome at long‐term follow‐up: a retrospective cohort study , 2000, Clinical endocrinology.

[54]  A. Baron,et al.  Polycystic Ovary Syndrome Is Associated With Endothelial Dysfunction , 2001, Circulation.

[55]  S. Johansson,et al.  Polycystic ovary syndrome and risk for myocardial infarction: Evaluated from a risk factor model based on a prospective population study of women , 1992, Acta obstetricia et gynecologica Scandinavica.

[56]  D. Playford,et al.  Non-invasive measurement of endothelial function , 1998 .

[57]  J. Connell,et al.  Altered vascular function in young women with polycystic ovary syndrome. , 2002, The Journal of clinical endocrinology and metabolism.

[58]  R. Norman,et al.  Metformin in polycystic ovary syndrome: systematic review and meta-analysis , 2003, BMJ : British Medical Journal.

[59]  L. Selvaggi,et al.  The Plasma Homocysteine Levels Are Increased in Polycystic Ovary Syndrome , 2002, Gynecologic and Obstetric Investigation.

[60]  S. Johansson,et al.  Hemostatic and metabolic variables in women with polycystic ovary syndrome. , 1994, Fertility and sterility.

[61]  B. Fauser,et al.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). , 2004, Human reproduction.

[62]  J. K. Lloyd,et al.  Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis , 1992, The Lancet.

[63]  R. Fox Prevalence of a positive family history of type 2 diabetes in women with polycystic ovarian disease. , 1999, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[64]  A. Dyer,et al.  Favorable cardiovascular risk profile in young women and long-term risk of cardiovascular and all-cause mortality. , 2004, JAMA.

[65]  A. Baron,et al.  Vascular function, insulin resistance and fatty acids , 2002, Diabetologia.

[66]  D. Jakubowicz,et al.  Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. , 1998, The Journal of clinical endocrinology and metabolism.

[67]  J. Manson,et al.  Menstrual cycle irregularity and risk for future cardiovascular disease. , 2002, The Journal of clinical endocrinology and metabolism.

[68]  R. Rizza Androgen effect on insulin action and glucose metabolism. , 2000, Mayo Clinic proceedings.

[69]  M. Adams,et al.  Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[70]  L. Kuller,et al.  Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. , 1996, American journal of obstetrics and gynecology.

[71]  M. Harma,et al.  Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. , 2001, Clinical biochemistry.

[72]  Peter Libby,et al.  Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. , 2002, JAMA.

[73]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[74]  J. Roman,et al.  Peroxisome Proliferator-Activated Receptor &ggr; Ligands Increase Release of Nitric Oxide From Endothelial Cells , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[75]  A. Pfeiffer,et al.  The polycystic ovary syndrome per se is not associated with increased chronic inflammation. , 2004, European journal of endocrinology.

[76]  A. Baron,et al.  Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. , 2003, The Journal of clinical endocrinology and metabolism.

[77]  A. Kitabchi,et al.  Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. , 1980, The Journal of clinical endocrinology and metabolism.

[78]  A. Kunselman,et al.  Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. , 2001, The American journal of medicine.

[79]  Judith R. Rager,et al.  Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. , 2004, The Journal of clinical endocrinology and metabolism.

[80]  P. Claman Men at risk: occupation and male infertility. , 2004, Fertility and sterility.

[81]  P. Björntorp,et al.  Anthropometric variables and metabolism in polycystic ovarian disease. , 1989, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[82]  Endogenous androgens and carotid intimal-medial thickness in women. , 1999, The Journal of clinical endocrinology and metabolism.

[83]  T. Kılıç,et al.  Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. , 2005, Human reproduction.

[84]  D. Webb,et al.  Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. , 1996, Circulation.

[85]  David Handelsman,et al.  Androgens and cardiovascular disease. , 2003, Endocrine reviews.

[86]  L. Kuller,et al.  Coronary heart disease risk factors in women with polycystic ovary syndrome. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[87]  G. Watts,et al.  Ventricular dysfunction in early diabetic heart disease: detection, mechanisms and significance. , 2003, Clinical science.

[88]  E. Diamanti-Kandarakis,et al.  Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. , 2001, The Journal of clinical endocrinology and metabolism.

[89]  P. Iozzo,et al.  Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. , 2002, Diabetes.

[90]  A. Malhotra,et al.  Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. , 2001, The Journal of clinical endocrinology and metabolism.

[91]  C. Duman,et al.  Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. , 2004, The Journal of clinical endocrinology and metabolism.

[92]  P Vallance,et al.  Heterogenous Nature of Flow-Mediated Dilatation in Human Conduit Arteries In Vivo: Relevance to Endothelial Dysfunction in Hypercholesterolemia , 2001, Circulation research.